Pear Therapeutics (NASDAQ: PEAR)
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-11-07 | ||||||
REV |
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | 0.040 | ||||||
REV | 3.297M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Pear Therapeutics (NASDAQ: PEAR) through any online brokerage.
Other companies in Pear Therapeutics’s space includes: Change Healthcare (NASDAQ:CHNG), MultiPlan (NYSE:MPLN), GoodRx Holdings (NASDAQ:GDRX), OptimizeRx (NASDAQ:OPRX) and Definitive Healthcare (NASDAQ:DH).
The latest price target for Pear Therapeutics (NASDAQ: PEAR) was reported by BTIG on Friday, August 12, 2022. The analyst firm set a price target for 5.00 expecting PEAR to rise to within 12 months (a possible 204.88% upside). 12 analyst firms have reported ratings in the last year.
The stock price for Pear Therapeutics (NASDAQ: PEAR) is $1.64 last updated August 17, 2022, 8:00 PM UTC.
There are no upcoming dividends for Pear Therapeutics.
Pear Therapeutics’s Q3 earnings are confirmed for Monday, November 7, 2022.
There is no upcoming split for Pear Therapeutics.
Pear Therapeutics is in the Health Care sector and Health Care Technology industry. They are listed on the NASDAQ.